Publication and Disclosure. Institution shall have the right to publish or present the results of Institution’s activities conducted under this Agreement, including Study Data, only in accordance with the requirements of this Section. All publications or presentations relating to this Agreement, the Study or data derived from this Study will be submitted to the Sponsor prior to any submission or presentation and Sponsor will approve all Publications in writing. Institution agrees to submit any proposed publication or presentation to Sponsor for review at least ninety (90) days prior to submitting any such proposed publication to a publisher or proceeding with such proposed presentation. Within ninety (90) days of its receipt, Sponsor shall advise Institution in writing of any information contained therein which is Confidential Information or which may impair the availability of patent protection for Inventions. Sponsor shall have the right to require Institution (a) to remove specifically identified Confidential Information prior to submitting or presenting the materials; 5.1 Publikování a zpřístupnění Zdravotnické zařízení bude oprávněno publikovat a prezentovat výsledky činnosti Zdravotnického zařízení, jež je prováděná na základě této Smlouvy, a to včetně Studijních dat a údajů, výlučně v souladu s požadavky stanovenými v tomto Článku. Všechny publikace nebo prezentace související s touto Smlouvou, se Studií nebo s údaji odvozenými ze Studie budou předkládány Zadavateli ještě před svým předložením nebo prezentací a Zadavatel schválí písemně všechny Publikace. Zdravotnické zařízení souhlasí, že Zadavateli předloží jakoukoli navrhovanou publikaci a prezentaci pro účely jejich kontroly ve lhůtě alespoň devadesáti (90) dnů před předložením jakékoli takové publikace příslušnému vydavateli či před jejich navrhovanou prezentací. Ve lhůtě devadesáti (90) dnů od jejich přijetí, Zadavatel se písemně vyjádří Zdravotnickému zařízení ve vztahu k jakékoli informaci obsažené v takových materiálech, jež představuje Důvěrnou informaci (nebo jež může představovat překážku možnosti dosažení patentové ochrany příslušného Objevu. Zadavatel bude oprávněn požadovat vůči Zdravotnickému zařízení: (a) odstranění definovaných informací označených jako Důvěrné informace ještě před předložením nebo prezentováním daných materiálů;
Publication and Disclosure. 18.1 Subject to the provisions of conditions 18.3, 18.4 and 18.6 and the Reports Schedule, the Contractor shall endeavour to make information about, and results from the Project generally available, and may do so provided he acknowledges in any public statement the financial support of the Authority.
Publication and Disclosure. Institution shall have the right to publish or present the results of Institution’s activities conducted under this Agreement, including Study Data, only in accordance with the requirements of this Section. Institution agrees to submit any proposed publication or presentation to Sponsor for review at least thirty (30) days prior to submitting any such proposed publication to a publisher or proceeding with such proposed presentation. Within thirty (30) days of its receipt, Sponsor shall advise Institution in writing of any information contained therein which is Confidential Information (other than Study Data) or which may impair the availability of patent protection for Inventions. Sponsor shall have the right to require Institution, to remove specifically identified Confidential Information (other than Study Data) and/or to delay the proposed publication or presentation for an additional sixty (60) days to enable Sponsor to seek patent protection for Inventions. 5.2
Publication and Disclosure. 3.1 Notwithstanding clause E6.1 but subject to clause E4 (Confidential Information) of the General Terms and Conditions (Section 2) and Schedule 4 (Commercially Sensitive Information), the Contractor shall endeavour to make the Results generally available (including in scientific journals where reasonably appropriate) and shall acknowledge in any public statement the financial support of the Authority and the Co-funders. The Contractor shall send details of any proposed publication to the Authority at least two weeks prior to the proposed publication and shall notify the Authority immediately if approached by the media about the Services.
Publication and Disclosure. Each Covered Stockholder hereby agrees to permit the Company and Parent to publish and disclose, including in filings with the SEC and in the press release announcing the transactions contemplated by the Merger Agreement, this Agreement and such Covered Stockholder’s identity and ownership of the Covered Shares and the nature of such Covered Stockholder’s commitments, arrangements and understandings under this Agreement.
Publication and Disclosure. In accordance with the requirements of this Section 5 (including but not limited to the time-restrictions for “Multi-Center Publications” (Section 5.2), “Confidentiality of Unpublished Data” (Section 5.3)), Institution and Investigator shall have the right to publish or present their Site Study results following from Site’s own activities conducted under this Agreement. Any proposed publication or presentation of the Site shall be consistent with scientific standards by (i) applying the highest industry standards, including but not limited to the Good Publication Practice and the Recommendations for Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals of the International Committee of Medical Journal Editors (ICMJE) in their current version and (ii) publishing Site Study Data first after the primary source publication of the Sponsor is made public. In addition, Institution and Investigator agree to submit any proposed publication or presentation to Sponsor’s Head of Global Medical Publication, email address: ▒▒▒▒▒▒▒▒▒▒▒▒▒ for review at least sixty (60) days prior to submitting any such proposed publication to a publisher or proceeding with such proposed presentation. Within sixty (60) days of its receipt, Sponsor shall advise Institution and/or Investigator, as the case may be, in writing of any information contained therein which is Confidential Information (other than Study Data) or which may impair the availability of patent protection for Inventions. Sponsor shall have the right to require Institution and/or Investigator, as applicable, to remove specifically identified Confidential Information (other than Study Data) and/or to delay the proposed publication or presentation for an additional sixty (60) days to enable Sponsor to seek patent protection for Inventions.
Publication and Disclosure. The Investigators shall have the right to publish the results of this Research subject to the terms of this Agreement. The subject matter of any such publication shall not contain AISC’s confidential or proprietary information nor shall it disclose any third party's proprietary or confidential information.
Publication and Disclosure. Each Stockholder hereby permits Parent and Purchaser to publish and disclose in its filings with the SEC under the Exchange Act, including the Offer Documents, and, if approval of the Company's stockholders is required under applicable law, the Proxy Statement (including all documents and schedules filed with the SEC), such Stockholder's identity and ownership of the Subject Shares and the nature of such Stockholder's commitments, arrangements and understandings under this Agreement.
Publication and Disclosure. Except as required by applicable Law (including without limitation the filing of a Schedule 13D or Schedule 13G or amendment thereto, as applicable, with the SEC which may include this Agreement as an exhibit thereto), the Covered Shareholder shall not, directly or indirectly, make any public announcement regarding this Agreement and the transactions contemplated hereby or with respect to the business or affairs of the Company, Parent or Sub, including the Merger Agreement and the Transactions, without the prior written consent of Parent; provided, however, that such consent shall not be required to the extent that any such announcement is consistent with the prior public announcements made by Parent or the Company in connection with this Agreement or the Merger Agreement or the transactions contemplated hereby or thereby. During the Term, (a) the Covered Shareholder shall permit and hereby authorizes Parent and the Company to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that Parent or the Company reasonably determines to be necessary or advisable in connection with the Merger and the Transactions, a copy of this Agreement, the Covered Shareholder’s identity and ownership of the Covered Shares and the nature of the Covered Shareholder’s commitments and obligations under this Agreement; and (b) Parent shall permit and hereby authorizes the Covered Shareholder and its affiliates, to the extent the Covered Shareholder or such affiliates are required to do so by applicable Law, to publish and disclose in all documents and schedules filed with the SEC (including any amendment to the Covered Shareholder’s Schedule 13D, as applicable), and any press release or other disclosure document in connection with the Merger and the Transactions, a copy of this Agreement, Parent’s identity and the nature of the Covered Shareholder’s commitments and obligations under this Agreement.
Publication and Disclosure. Institution and Principal Investigator shall have the right to publish, present or otherwise publicly disclose the results of and disseminate information pertaining to the activities conducted under this Agreement and in accordance with the requirements of this Section 8.0. Institution and Principal Investigator shall include the register and xxxxxxxxxxxxxx.xxx identifier in the abstract of any publication. Institution and Principal Investigator agree to submit any proposed publication, presentation or other public disclosure to Sponsor for review at least thirty (30) days prior to submitting such proposed publication, presentation or other public disclosure to a publisher or other third party. Within thirty (30) days of its receipt, Sponsor shall advise Institution and/or Principal Investigator, as the case may be, in writing of any information contained therein which is Confidential Information (as defined in Section 10.1) (other than Study Data) or which may impair Sponsor’s ability to obtain patent protection. Sponsor shall have the right to require Institution and/or Principal Investigator, as applicable, to remove specifically identified Confidential Information (other than Study Data) and to delay the proposed publication, presentation or other public disclosure for an additional ninety (90) days to enable Sponsor to seek patent protection. 8.1
